This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Paranoid schizophrenia편집조현병 (편집형정신분열증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: F20.0 (paranoid schizophrenia) | Special Copayment Reduction: V161 (severe intractable disease, copayment reduced for 5 years after registration)
B. SynonymsParanoid schizophrenia
C. Adult onsetLikelihood of first onset in adulthood: high - paranoid schizophrenia has the latest age of onset among schizophrenia subtypes, with first diagnosis often at ages 25-35 in men and 25-40 in women, and first onset in adults in their 40s-50s is not uncommon.
1. History19th century: Kahlbaum and Kraepelin's description of dementia praecox → 1911: Bleuler names "schizophrenia" → paranoid subtype established in ICD and DSM → 2013: subtypes abolished in DSM-5, retained in ICD-10 and ICD-11.
2. CausesCombined action of genetic vulnerability (overall heritability of schizophrenia 60-80%), neurodevelopmental abnormality, dopamine overactivity, and environmental stress (immigration, urban residence, traumatic experience).
3. GeneticsMore than 100 risk loci identified in GWAS (CACNA1C, DISC1, NRG1, DTNBP1, etc.); 22q11.2 deletion (velo-cardio-facial syndrome) CNV increases schizophrenia risk 22-fold.
4. General epidemiologyLifetime prevalence of schizophrenia overall about 0.7-1%; paranoid type is the most common subtype (40-50% of the total). About 110,000 registered schizophrenia patients in Korea (2022, National Health Insurance basis).
5. PathophysiologyMesolimbic dopamine overactivity causes positive symptoms (delusions, hallucinations); prefrontal dopamine hypoactivity contributes to cognitive deficits; glutamate NMDA receptor dysfunction is also a core mechanism.
6. SymptomsPersecutory, referential, and grandiose delusions are the main symptoms; third-person auditory hallucinations (voices that comment or command); thinking relatively preserved; affective blunting relatively mild.
7. SignsOn mental status examination: delusional thought content, behavior in response to hallucinations (muttering to oneself, listening intently), wariness, suspiciousness, hostile attitude; cognitive function and grooming relatively preserved.
8. ScreeningPROD interview, PANSS positive scale, assessment of comorbid substance use with AUDIT and DAST; structured screening interview within early intervention programs for high-risk groups (first-episode psychosis).
9. DiagnosisApply ICD-10 F20.0 or DSM-5 schizophrenia criteria; differential diagnosis: delusional disorder, schizoaffective disorder, organic psychosis; exclude organic causes with brain MRI, EEG, and blood tests.
10. TreatmentSecond-generation antipsychotics (olanzapine, risperidone, aripiprazole, etc.) first line; clozapine for refractory cases; LAI (long-acting injectables); CBT, family therapy, and case management in parallel.
11. PrognosisBest prognosis among schizophrenia subtypes; about 20-30% achieve substantial functional recovery; prognosis is better with later onset, good premorbid functioning, and female sex.
12. PreventionEarly intervention for first-episode psychosis, monitoring of high-risk adolescents, prevention of substance abuse, strengthening social support; maintenance pharmacotherapy combined with psychosocial treatment for relapse prevention.
13. ReferencesLeucht S, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 … and 9 other papers

1. History

The history of paranoid schizophrenia unfolded alongside the systematization of European psychiatry in the 19th century. In 1863, the German Karl Ludwig Kahlbaum advocated classifying mental illness according to clinical course, and in 1874 he introduced the concept of "paranoia," describing systematized delusional states of persecutory and grandiose thinking. His student Ewald Hecker described hebephrenia in 1871, and Kahlbaum himself described katatonia in 1874, laying the foundation for the classification of schizophrenia subtypes.

The most influential figure in modern psychiatry was the German Emil Kraepelin. In the fourth edition of his psychiatry textbook in 1893, Kraepelin established the concept of "dementia praecox," and in the fifth edition in 1896 he included three subtypes: paranoid type, hebephrenic type, and catatonic type. He emphasized that paranoid dementia praecox has a later age of onset and a relatively better course than the other subtypes. Kraepelin's classification became the foundation of the subsequent diagnostic system for schizophrenia.

In 1911, the Swiss Eugen Bleuler extended Kraepelin's concept of dementia praecox and proposed the new name "schizophrenia." Bleuler presented the 4 A's (loosening of associations, affective blunting, ambivalence, autism) as fundamental symptoms and regarded delusions and hallucinations as accessory symptoms. He recognized paranoid schizophrenia as a separate subtype but held that the core pathology lies in disturbances of association and affect.

From the mid-20th century, international standardization of classification systems progressed. Both the World Health Organization (WHO) ICD-9 (1978) and the American Psychiatric Association (APA) DSM-III (1980) included paranoid schizophrenia as an independent subtype. ICD-10 (1992) classified paranoid schizophrenia as F20.0, and DSM-IV (1994) also specified the paranoid type. In Korea, when the Korean Standard Classification of Diseases adopted ICD-10 in 1995, it was officially classified as "pyeonjipyeong johyeonbyeong" or "pyeonjipyeong jeongsinbunyeoljeung" (both meaning paranoid schizophrenia), and since 2012 "jeongsinbunyeolbyeong" (the former Korean name for schizophrenia) has been renamed "johyeonbyeong."

DSM-5, published in 2013, abolished the previous subtype classification (paranoid, hebephrenic, catatonic, etc.) and, instead of integrating schizophrenia into a single diagnosis, changed to assessing it along dimensions of positive, negative, and cognitive symptoms. The reasons were unclear boundaries between subtypes, longitudinal instability, and lack of neurobiological basis. In contrast, ICD-10 and ICD-11 retained the paranoid schizophrenia subtype. ICD-11 (2022) took a compromise approach, consolidating into "schizophrenia (6A20)" while describing positive, negative, depressive, manic, psychomotor, and cognitive symptoms with symptom specifiers. Currently in Korean clinical practice, the ICD-10 F20.0 code is used for insurance claims and Special Copayment Reduction.


2. Causes

The cause of paranoid schizophrenia cannot be explained by a single causal factor and is understood as a combined action of genetic vulnerability, neurodevelopmental abnormality, neurochemical imbalance, and various environmental factors. This is called the vulnerability-stress model or the diathesis-environment interaction model.

Genetic factors: The heritability of schizophrenia is reported at about 60-80% in twin studies. The concordance risk in monozygotic twins is about 41-65%, markedly higher than in dizygotic twins (about 15%) or ordinary siblings (about 6-9%). The risk of onset in first-degree relatives of schizophrenia patients is about 10 times that of the general population. Familial clustering is observed for the paranoid subtype, but the subtype-specific genetic pattern has not yet been clearly established.

Neurodevelopmental abnormality: Evidence has accumulated that disturbance in the fetal and early neurodevelopmental stages forms the predisposition to schizophrenia. Influenza infection in the second trimester of pregnancy, nutritional deficiency (folate deficiency), and pregnancy complications (hypoxia, intrauterine growth restriction) are reported to increase the risk of schizophrenia. Abnormal early neuronal migration and abnormal prefrontal connectivity are confirmed in postmortem brain studies. Longitudinal studies showing mild cognitive and social abnormalities in people who later develop schizophrenia even before school age support the neurodevelopmental origin theory.

Neurochemical factors: Abnormality of the dopamine system is central: mesolimbic dopamine overactivity causes positive symptoms such as delusions and hallucinations, and mesocortical dopamine hypoactivity contributes to negative symptoms and cognitive deficits. Hypofunction of the glutamate NMDA receptor is also an important mechanism, and the fact that NMDA antagonists such as ketamine induce schizophrenia-like symptoms supports this hypothesis. The serotonin, GABA, and acetylcholine systems are also involved in the pathophysiology.

Environmental and social factors: Urban residence, immigration experience, social isolation, trauma, childhood abuse, and use of psychoactive substances such as cannabis increase the risk of schizophrenia onset. In particular, a meta-analysis found that use of high-potency cannabis (high THC content) raises the risk of schizophrenia onset 2-3 fold. The higher prevalence of schizophrenia among immigrants and ethnic minorities is explained by dopamine overactivity associated with social defeat and chronic stress.

Specific causal factors of the paranoid subtype: Paranoid schizophrenia often has a later age of onset and good premorbid functioning compared with other subtypes. This suggests that the genetic loading is relatively low and environmental precipitating factors play a larger role. A cognitive model has been proposed in which persecutory cognitive bias and a distrust-based attributional style precede the formation of paranoid delusions.


3. Genetics

Genetic research on schizophrenia has made breakthrough progress over the past 20 years with the advance of large-scale genome studies. The genetic predisposition applying to schizophrenia as a whole, including paranoid schizophrenia, has a polygenic structure. That is, hundreds to thousands of gene variants each contribute a small amount of risk and together constitute the overall genetic vulnerability.

Major GWAS results: In 2022, the schizophrenia GWAS consortium (PGC-SCZ3) analyzed case-control data from more than 287,000 people and identified 287 independent schizophrenia-associated genomic risk loci. Many of these are located near genes related to neurodevelopment, synaptic transmission, and ion channel function. Genes of note include CACNA1C (L-type calcium channel), GRIN2A (NMDA receptor subunit), the MHC region (immune gene complex), NRXN1 (synaptic adhesion protein), and DISC1 (Disrupted in schizophrenia 1).

Copy Number Variants (CNV): Rare CNVs with large effect sizes contribute to schizophrenia risk. 22q11.2 deletion (DiGeorge/velo-cardio-facial syndrome) increases schizophrenia risk about 22-32 fold, and schizophrenia develops in about 25-30% of carriers of this deletion. 1q21.1 deletion/duplication, 15q11.2 deletion, and 16p11.2 deletion/duplication are also reported as risk CNVs. Each of these CNVs is found in less than 1% of schizophrenia patients, but the individual effect size is large and the clinical significance is clear.

Rare single nucleotide variants (rare SNV/indel): Exome sequencing studies have confirmed that rare loss-of-function variants in genes such as SETD1A, NRXN1, and RB1CC1 are associated with schizophrenia risk. These genes are involved in neurodevelopment and synaptic maintenance, and a single variant alone can increase risk several tens of fold.

Polygenic Risk Score (PRS): The schizophrenia PRS is used to predict schizophrenia onset in large populations, and evidence for clinical application is currently accumulating. Individuals in the top 10% of PRS have a 3-5 fold risk of onset compared with the general population. Its specificity is still limited for direct use in individual clinical diagnosis, but it is useful for monitoring high-risk groups and for early intervention research.

Genetic characteristics of the paranoid subtype: Subtype-specific genetic research in schizophrenia is limited by sample size. Some studies report a tendency for paranoid schizophrenia to have a lower genetic loading and a larger relative contribution of environmental factors than hebephrenic schizophrenia, but this is not conclusive. Since the subtypes were abolished in DSM-5, the latest large-scale studies are conducted on schizophrenia as a whole without distinguishing subtypes.


4. General epidemiology

Schizophrenia, including paranoid schizophrenia, is a serious mental illness occurring in all cultures and socioeconomic groups worldwide. According to the WHO Global Burden of Disease study, the worldwide lifetime prevalence of schizophrenia is consistently reported at about 0.7-1.0%, and the annual incidence is about 15-20 per 100,000 population.

Sex differences: Men tend to have first onset at about 18-25 years and women at about 25-35 years, showing a sex difference of about 5-7 years in mean age of onset. In men, onset is earlier and negative symptoms and cognitive deficits are prominent, whereas in women paranoid symptoms and affective symptoms are relatively more common. This is partly explained by the hypothesis that estrogen modulates dopamine receptor sensitivity. Paranoid schizophrenia has a relatively higher proportion in women, and given its later age of onset, a second peak of onset (40s-50s) is prominent in women.

Epidemiologic characteristics of the paranoid type: Under the ICD-10 classification, the paranoid type is the most common subtype, accounting for about 40-50% of all schizophrenia diagnoses. The age of onset is on average 5-10 years later than other subtypes, and the premorbid functional level is relatively good. The association with lowered socioeconomic status is common to schizophrenia as a whole and is explained by the phenomenon of social "drift" after onset. A difference in prevalence between urban and rural areas (about 2-fold higher in urban areas) is observed and is associated with urban environmental stress and dopamine overactivity.

Epidemiology in Korea: According to Health Insurance Review & Assessment Service (HIRA) data, the number of patients treated for schizophrenia (F20) in 2022 was about 110,000, of whom F20.0 paranoid schizophrenia accounted for the highest proportion. The prevalence in Korea is reported at about 2.2 per 1,000 population (2019 Mental Disorders Survey). The hospitalization rate of schizophrenia patients has recently been decreasing with strengthened community-based treatment, but a considerable number of patients still experience long-term hospitalization. With Special Copayment Reduction (V161) registration in Korea, copayments for outpatient care and hospitalization are reduced.

Socioeconomic burden: Schizophrenia is one of the mental illnesses that is a leading cause of disability worldwide. In the WHO disability-adjusted life years (DALY) calculation, schizophrenia ranks within the top 15 of all diseases. Occupational and social function is impaired in about 50-80% of schizophrenia patients, and the unemployment rate is 3-5 times higher than in the general population. However, paranoid schizophrenia tends to have relatively better preservation of social function than other subtypes.


5. Pathophysiology

The pathophysiology of paranoid schizophrenia is being studied in a multifaceted way at the neurochemical, neurocircuit, immunologic, and epigenetic levels. The best-established mechanism is the dopamine hypothesis, but multilayered models going beyond it are the current mainstream.

Dopamine hypothesis: D2 receptor overactivity in the mesolimbic pathway causes positive symptoms such as persecutory delusions, referential delusions, and auditory hallucinations. PET studies have confirmed that striatal dopamine synthesis capacity and release in schizophrenia patients are significantly higher than in controls. The fact that D2 blockade is the core mechanism of action of all first-generation and most second-generation antipsychotics strongly supports this hypothesis. The prominence of positive symptoms in the paranoid type is explained by particularly prominent limbic dopamine overactivity. On the other hand, dopamine hypoactivity in the prefrontal cortex (PFC) contributes to negative symptoms and cognitive deficits, and in the paranoid type this PFC dysfunction is relatively slight, so cognition is better preserved.

Glutamate/NMDA receptor hypothesis: The basis of this hypothesis is that NMDA receptor antagonists (ketamine, PCP) induce schizophrenia-like symptoms (delusions, hallucinations, negative symptoms, and cognitive deficits, all of them). Hypofunction of the NMDA receptor decreases the activity of cortical GABA interneurons (inhibitory neurons), causing cortical hyperexcitability and abnormal gamma oscillation. An integrated model has been proposed in which this hyperexcitability amplifies limbic dopamine release, leading to positive symptoms.

Cognitive neuroscience mechanism of paranoid delusions: The persecutory delusion characteristic of the paranoid type is explained by the "aberrant salience" mechanism. Overactive dopamine assigns excessive meaning (salience) to irrelevant stimuli, and cognitive attempts to explain this crystallize into a delusional system. Attribution bias - the tendency to attribute negative events to external, personal causes - is associated with the paranoid cognitive style and is a target of psychotherapy.

Immunologic mechanism: Microglial activation, blood-brain barrier dysfunction, and elevation of inflammatory cytokines (IL-6, TNF-α, IL-1β) are reported in schizophrenia patients. Autoimmune encephalitis (encephalitis associated with NMDAR, LGI1, and CASPR2 antibodies) can cause schizophrenia-like symptoms, so excluding an autoimmune cause in first-episode psychosis is important. The possibility that the anti-inflammatory effects of some antipsychotics contribute to treatment response is being studied.


6. Symptoms

The clinical symptoms of paranoid schizophrenia center on persistent delusions and auditory hallucinations, with thought organization and emotional expression relatively preserved compared with other subtypes.

Persecutory delusion: The most common type of delusion, a firm belief that other people or groups are watching, following, or trying to harm the patient. The content of the delusion is relatively systematized, and patients often explain it with logical consistency. They may name specific persecutors such as neighbors, coworkers, government agencies, or intelligence agencies.

Delusion of reference: A belief that surrounding events, media content, or other people's behavior have special relevance to oneself. It appears in forms such as interpreting a particular phrase in TV news as a message sent to oneself, or being convinced that people passing on the street are laughing at oneself.

Grandiose delusion: A belief that one has special abilities, a mission, or an identity, often appearing together with persecutory delusions. Common content is that one is a messenger of God or a person assigned a special mission.

Auditory hallucination: The most characteristic hallucination in paranoid schizophrenia, typically third-person voices that comment on or command the patient's behavior (running commentary, command hallucination). In some cases several voices converse with each other. The voices are heard as vividly as real ones, and behavior of muttering to oneself or listening intently in response is observed. Visual, olfactory, and tactile hallucinations rarely accompany.

Thought transmission symptoms: First-rank Schneiderian symptoms may appear, such as thought broadcasting (one's thoughts are transmitted to others), thought insertion (thoughts are inserted from outside), and thought withdrawal (one's thoughts are taken away).

Affective and negative symptoms: In the paranoid type, negative symptoms such as affective flattening, avolition, and alogia are milder or less prominent than in the hebephrenic and residual types. However, anxiety, wariness, anger, and hostility may appear in connection with delusions, and aggression may increase in the active phase.


7. Signs

The clinical signs of patients with paranoid schizophrenia are systematically assessed in the mental status examination (MSE). Signs differ between the active phase and the remission phase, and grooming, thought organization, and basic cognitive function are relatively preserved compared with other schizophrenia subtypes.

Appearance and behavior: Appearance and self-care tend to be maintained relatively well, but attention may decrease as the illness progresses or in the active phase. Wariness, suspiciousness, and a tense posture toward the interviewer are observed. Behavior in response to auditory hallucinations (talking to oneself, listening or pointing, sudden laughter or anger) appears. A defensive or avoidant attitude may make cooperation in the interview difficult.

Speech and thought: In thought content, delusions are prominent, and there is a tendency to explain the logic of the delusion in detail. Thought form is relatively organized and is comparatively understandable compared with the hebephrenic and undifferentiated types. However, circumstantiality that over-explains delusional reference, or excess of information, may be observed.

Affect and mood: Affect often matches the content of the delusion - anxiety, fear, and anger in delusions of persecutory content, and elation and excitement in grandiose content. Affective blunting is milder than in the hebephrenic type. Depressive symptoms may co-occur, and a transition to a depressive episode after the delusions subside may occur (→ differentiation from F20.4 post-schizophrenic depression is needed).

Cognitive function: Paranoid schizophrenia has relatively milder cognitive impairment than other subtypes, but decline in working memory, processing speed, and executive function is confirmed on neuropsychological testing. Objective assessment is possible with standardized cognitive tests such as the MATRICS Consensus Cognitive Battery (MCCB).

Insight: In paranoid-type patients, insight into recognizing one's own symptoms as pathological is often reduced. This is a main cause of treatment refusal, poor medication adherence, and loss to outpatient follow-up. Standard tools such as the Birchwood Insight Scale and SUMD (Schedule for the Assessment of Insight) are used to assess insight.


8. Screening

For schizophrenia, including paranoid schizophrenia, no biological screening test for the general population has been established. However, because early detection at the clinical high risk (CHR) or first-episode psychosis (FEP) stage has a decisive effect on long-term prognosis, structured clinical screening and early intervention are the core strategy of modern mental health systems.

Early psychosis risk screening tools: SIPS/SOPS (Structured Interview for Psychosis-Risk Syndromes) and CAARMS (Comprehensive Assessment of At-Risk Mental States) are used as international standards, structured tools for assessing the psychosis prodromal period. These tools integrate attenuated psychotic symptoms, brief intermittent psychosis, genetic risk, and functional decline to determine CHR status. The PROD scale (Prodromal Scale) is a self-report and clinician-rated tool useful for initial screening of prodromal symptoms.

Positive symptom rating scales: The PANSS (Positive and Negative Syndrome Scale) positive subscale, BPRS (Brief Psychiatric Rating Scale), and SAPS (Scale for the Assessment of Positive Symptoms) are used to assess the severity of paranoid symptoms. These tools are also important for monitoring treatment response.

Screening in primary care and emergency settings: Simple screening tools (e.g., 6-item PANSS, PQ-16) may be used to detect schizophrenia early in non-mental-health settings such as internal medicine and emergency care. Referral to psychiatry is recommended when red flags such as behavioral or thought abnormalities, abrupt decline in social function, sleep disturbance, and risk of self-harm or harm to others are present.

Screening for comorbid conditions: Substance use disorders (cannabis, stimulants), depressive and anxiety disorders, and posttraumatic stress disorder (PTSD) are conditions that accompany paranoid symptoms or need to be differentiated, and standard screening tools such as AUDIT (alcohol), DAST (drug use), PHQ-9 (depression), and PCL-5 (PTSD) are used in parallel.


9. Diagnosis

Diagnosis of paranoid schizophrenia centers on symptom assessment based on clinical interview, and differentiation from organic psychosis and other mental disorders is essential.

ICD-10 F20.0 diagnostic criteria: ICD-10 F20.0 paranoid schizophrenia is diagnosed when the general criteria for schizophrenia (F20) are met and ① relatively stable delusions (mainly persecutory, referential, grandiose, bodily, and jealousy delusions), accompanied by auditory or other hallucinations, dominate the clinical picture, ② flat or inappropriate affect, even if present, does not dominate the clinical picture, and ③ thought disorder is not prominent. The general criteria for schizophrenia require characteristic symptoms (two or more of delusions, auditory hallucinations, thought disorder, negative symptoms) for at least 1 month.

Application of DSM-5: DSM-5 abolished the subtype classification and makes a single diagnosis of schizophrenia, but in clinical practice the concept of the paranoid type is still used to describe paranoid clinical features. The DSM-5 diagnostic criteria for schizophrenia consist of A (two or more characteristic symptoms, at least 1 month), B (decline in social/occupational function), C (persistence for 6 months or more), D (exclusion of schizoaffective disorder and bipolar disorder), E (exclusion of substance and medical conditions), and F (exclusion of autism spectrum disorder).

Differential diagnosis: ① Delusional disorder (F22): only non-bizarre delusions are present, with function preserved and no negative symptoms, prominent auditory hallucinations, or thought disorder. ② Schizoaffective disorder (F25): schizophrenia symptoms and mood episodes are met simultaneously. ③ Organic causes: psychosis due to brain tumor, temporal lobe epilepsy, autoimmune encephalitis (NMDAR antibody, etc.), or drugs (steroids, amphetamine, dopaminergic agents). ④ Manic episode: grandiose delusions and auditory hallucinations may accompany, but the mood episode is in the foreground.

Essential tests: Blood tests (complete blood count, metabolic panel, thyroid function, B12 and folate, syphilis, HIV, autoimmune antibodies), urine drug screen, brain MRI (to exclude organic lesions), electroencephalography (EEG, to exclude epilepsy). CSF antibody testing when autoimmune encephalitis such as NMDAR encephalitis is suspected.


10. Treatment

The standard treatment for paranoid schizophrenia is a multidisciplinary approach centered on antipsychotic pharmacotherapy and integrating psychosocial treatment, rehabilitation, and community support.

Antipsychotics - first-line treatment: Second-generation (atypical) antipsychotics are the first choice. Olanzapine, risperidone, quetiapine, aripiprazole, paliperidone, ziprasidone, and amisulpride are widely used. A 2013 Lancet meta-analysis (Leucht et al.) confirmed that olanzapine, clozapine, and amisulpride have superior overall efficacy. D2 receptor blockade is the core mechanism for positive symptoms such as persecutory delusions and auditory hallucinations, and an adequate dose and a treatment period of at least 4-6 weeks are needed to judge efficacy. Dose adjustment is considered for a partial response after 2-4 weeks of administration, and a change of drug is considered for an insufficient response after 4-6 weeks.

Clozapine: The gold-standard treatment for treatment-resistant schizophrenia that does not respond adequately to two or more antipsychotics. Treatment resistance is usually defined as persistence of symptoms after treatment at adequate doses for 6 weeks or more each with two or more drugs (of different classes). Clozapine requires regular blood monitoring because of the risk of neutropenia (agranulocytosis). It is also the only antipsychotic with an FDA-approved indication for reducing suicide risk.

Long-Acting Injectable (LAI): LAIs are recommended to reduce dependence on daily medication and improve treatment adherence. They include paliperidone palmitate (Invega Sustenna, 1 month; Invega Trinza, 3 months), risperidone microspheres (Risperdal Consta), aripiprazole monohydrate (Abilify Maintena), and olanzapine pamoate (Zyprexa Relprevv). LAIs are effective for relapse prevention, reduced rehospitalization, and improved quality of life.

Psychotherapy: Cognitive behavioral therapy (CBT) is an evidence-based psychotherapy for paranoid symptoms, including examination of evidence for delusional beliefs, correction of attribution bias, and management of stress vulnerability. The UK NICE guideline recommends offering CBT to all schizophrenia patients. Family psychoeducation and family therapy are effective for relapse prevention and reducing caregiver burden.

Community treatment and rehabilitation: Assertive Community Treatment (ACT), supported employment, social skills training, and cognitive rehabilitation contribute to functional recovery. In Korea, community mental health welfare centers, psychiatric rehabilitation facilities, and day hospital programs support community maintenance.


11. Prognosis

Paranoid schizophrenia has traditionally been known to have the best prognosis among schizophrenia subtypes. This is because the age of onset is relatively late, premorbid function is good, and negative symptoms and cognitive deficits are less prominent.

Functional recovery: In long-term follow-up studies, about 20-30% of schizophrenia patients achieve substantial functional recovery (social recovery), and this proportion is relatively high in the paranoid type. In the 20-year follow-up study of Jobe and Harrow (2005), about 40% of paranoid-type patients experienced a substantial level of remission. About 80% of first-episode schizophrenia patients achieve remission in the first episode, but the relapse rate is high, and about 80% experience relapse within 5 years.

Relapse and chronicity: When medication is stopped after the first episode, the relapse rate within 2 years reaches about 80%, and the more relapses there are, the harder functional recovery becomes. Maintenance antipsychotic pharmacotherapy is most effective for relapse prevention, and LAI use is advantageous for maintaining adherence. Substance abuse, stressful life events, and high expressed emotion within the family are risk factors for relapse.

Mortality: The life expectancy of schizophrenia patients is about 10-15 years shorter than that of the general population. Suicide is the main cause of death, with a lifetime suicide attempt rate of about 20-40% and a completed suicide rate of about 4-10% reported. Deaths from physical health problems such as cardiovascular disease, diabetes, and respiratory disease are also high. Early intervention and integrated physical health care are key to reducing this gap.

Prognostic predictors: Good prognostic factors include later age of onset, female sex, good premorbid social and occupational function, acute onset, family support, treatment adherence, and no substance use. Poor prognostic factors are early age of onset, male sex, impaired premorbid function, prominent negative symptoms, substance use, treatment nonadherence, and an isolated social environment.


12. Prevention

Prevention of schizophrenia, including paranoid schizophrenia, consists of primary (preventing onset), secondary (early detection and intervention), and tertiary (preventing relapse and functional decline) prevention.

Primary prevention: Complete primary prevention has not yet been established, but reducing identified risk factors corresponds to it. This includes infection prevention in pregnant women (influenza vaccination), prenatal nutritional management (folate supplementation), prevention of perinatal complications, and prevention of child abuse and trauma. Prevention of cannabis use in adolescence is important for reducing the risk of schizophrenia onset.

Secondary prevention - early intervention: Early detection of first-episode psychosis (FEP) and prompt access to treatment determine long-term prognosis. Shortening the duration of untreated psychosis (DUP) has a significant effect on treatment response, remission rate, and relapse rate. Early Intervention in Psychosis (EIP) programs are spreading worldwide, and Korea is also expanding mental health early intervention services. Mental health literacy education in schools and communities promotes symptom recognition and help-seeking behavior.

Tertiary prevention - relapse prevention and maintenance of function: The core elements are maintenance antipsychotic pharmacotherapy (at least 1-2 years; long-term or lifelong for patients with multiple episodes), cognitive behavioral therapy and family education, linkage to community support services, treatment of substance use, and physical health monitoring (metabolic syndrome, diabetes, cardiovascular risk management). Suicide risk assessment and safety planning are essential items of regular follow-up.


13. References

  1. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. DOI: 10.1016/S0140-6736(13)60733-3. PMID: 23810019.

  2. Trubetskoy V, Pardiñas AF, Qi T, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022;604(7906):502-508. DOI: 10.1038/s41586-022-04434-5. PMID: 35396580.

  3. Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067. DOI: 10.1038/nrdp.2015.67. PMID: 27189524.

  4. Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014;383(9929):1677-1687. DOI: 10.1016/S0140-6736(13)62036-X. PMID: 24315522.

  5. National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. NICE guideline CG178. 2014 (updated 2019). Available at: https://www.nice.org.uk/guidance/cg178.

  6. Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149-160. DOI: 10.1002/wps.20516. PMID: 29745131.

  7. Mueser KT, McGurk SR. Schizophrenia. Lancet. 2004;363(9426):2063-2072. DOI: 10.1016/S0140-6736(04)16458-1. PMID: 15207959.

  8. Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022;399(10323):473-486. DOI: 10.1016/S0140-6736(21)01730-X. PMID: 35093236.

  9. Park SC, Jang EY, Park YC. Prevalence, correlates, and impact of schizophrenia on daily life in Korea: a population-based study. Psychiatry Investig. 2018;15(6):580-586. DOI: 10.30773/pi.2017.11.16. PMID: 29961308.

  10. Kane JM, Correll CU. Optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry. 2010;71(Suppl 3):27-33. DOI: 10.4088/JCP.9096su1cc.05. PMID: 20492834.